Craig Hallum initiated coverage on BioHarvest Sciences with a new price target
$BHST
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $15.00 | Buy | Craig Hallum |
| 12/18/2024 | $12.00 | Buy | Maxim Group |
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis ProcessRehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.Ahead of the sig
New York, May 21, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on BioHarvest Sciences Inc. (NASDAQ:BHST). The update note includes detailed information on the BioHarvest Sciences' financial results, operational updates, business model, management commentary, valuation, and risks. The update note is available below. BioHarvest Sciences May 2025 Update Note Highlights from the note include: Q1 Results Surpass Expectations on VINIA Strength and Operating Efficiencies: BioHarvest Sciences reported robust financial performance for the first quarter of 2025, with rev
First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.
Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter
Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division